The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
Abbott ID NOW CoV-2 molecular point-of-care test for novel coronavirus Abbott has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. What makes this test so different is where it can be used: outside the four walls of a traditional hospital such as in the physicians' office or urgent care clinics. The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOWTM platform--a lightweight box (6.6 pounds and the size of a small toaster) that can sit in a variety of locations. Because of its small size, it can be used in more non-traditional places where people can have their results in a matter of minutes, bringing an alternate testing technology to combat the novel coronavirus. We're ramping up production to deliver 50,000 ID NOW COVID-19 tests per day, beginning next week, to the U.S. healthcare system. This comes on the heels of our announcement last week of the availability of the Abbott RealTime SARS-CoV-2 EUA test under FDA EUA, which runs on m2000 RealTime molecular system for centralized lab environments. Combined with ID NOW, Abbott expects to produce about 5 million tests in April.
Abbott has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.
What makes this test so different is where it can be used: outside the four walls of a traditional hospital such as in the physicians' office or urgent care clinics.
The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOWTM platform--a lightweight box (6.6 pounds and the size of a small toaster) that can sit in a variety of locations.
Because of its small size, it can be used in more non-traditional places where people can have their results in a matter of minutes, bringing an alternate testing technology to combat the novel coronavirus.
We're ramping up production to deliver 50,000 ID NOW COVID-19 tests per day, beginning next week, to the U.S. healthcare system.
This comes on the heels of our announcement last week of the availability of the Abbott RealTime SARS-CoV-2 EUA test under FDA EUA, which runs on m2000 RealTime molecular system for centralized lab environments. Combined with ID NOW, Abbott expects to produce about 5 million tests in April.
○ How It Works: Portable Coronavirus Teating
○ Formerly AlereTM i. New and Improved Speed, Performance and Efficiency. Plus a new name.
Reviews: "The Alere I is constantly being sent in for service. The touch pad stops working at regular intervals. The mechanical parts of the machine break often. I have the machine for free if I buy test kits. If I had purchased the machine outright I would have been fuming mad."
by ATinNM - Jan 26 2 comments
by Frank Schnittger - Jan 24 26 comments
by Oui - Jan 26 2 comments
by Oui - Jan 20 56 comments
by Oui - Jan 23 32 comments
by gmoke - Jan 24
by Frank Schnittger - Jan 14 58 comments
by gmoke - Jan 22 2 comments
by Oui - Jan 27
by Oui - Jan 262 comments
by ATinNM - Jan 262 comments
by Frank Schnittger - Jan 2426 comments
by Oui - Jan 2332 comments
by gmoke - Jan 222 comments
by Oui - Jan 2110 comments
by Oui - Jan 2056 comments
by Oui - Jan 2013 comments
by Oui - Jan 172 comments
by Oui - Jan 1610 comments
by gmoke - Jan 16
by IdiotSavant - Jan 1521 comments
by Oui - Jan 1453 comments
by Frank Schnittger - Jan 1458 comments
by Oui - Jan 1390 comments
by Oui - Jan 1177 comments
by Oui - Jan 1061 comments
by Frank Schnittger - Jan 877 comments